Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken

[1]  J. Lünemann,et al.  Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. , 2007, Annals of neurology.

[2]  Steven A Greenberg,et al.  Evaluation and construction of diagnostic criteria for inclusion body myositis , 2014, Neurology.

[3]  P H Plotz,et al.  The Treatment of Inclusion Body Myositis: A Retrospective Review and a Randomized, Prospective Trial of Immunosuppressive , 1993, Medicine.

[4]  A. Zwinderman,et al.  Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo , 2002, Annals of neurology.

[5]  K. Myburgh,et al.  Variable inflammation and intramuscular STAT3 phosphorylation and myeloperoxidase levels after downhill running , 2014, Scandinavian journal of medicine & science in sports.

[6]  D. Selkoe,et al.  Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. , 1994, The American journal of pathology.

[7]  S. Welle,et al.  Ragged Red Fibers in Normal Aging and Inflammatory Myopathy , 1995, Annals of neurology.

[8]  Anthony A Amato,et al.  Unicorns, dragons, polymyositis, and other mythological beasts , 2003, Neurology.

[9]  F. Breedveld,et al.  Epidemiology of inclusion body myositis in the Netherlands: A nationwide study , 2000, Neurology.

[10]  B. Engelen,et al.  Autoantibodies to cytosolic 5′‐nucleotidase 1A in inclusion body myositis , 2013, Annals of neurology.

[11]  M. Dalakas,et al.  Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle , 2008, Brain : a journal of neurology.

[12]  S. Spector,et al.  A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM , 2001, Neurology.

[13]  M. Sandri,et al.  Proteotoxicity: an underappreciated pathology in cardiac disease. , 2014, Journal of molecular and cellular cardiology.

[14]  V. Dubowitz,et al.  INCREASED EXPRESSION OF HLA ABC CLASS I ANTIGENS BY MUSCLE FIBRES IN DUCHENNE MUSCULAR DYSTROPHY, INFLAMMATORY MYOPATHY, AND OTHER NEUROMUSCULAR DISORDERS , 1985, The Lancet.

[15]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[16]  I. James,et al.  High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: An analysis of disease-associated alleles and diplotypes , 2012, Journal of Neuroimmunology.

[17]  E. Hoffman,et al.  Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. , 2005, Arthritis and rheumatism.

[18]  W. Engel,et al.  Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis. , 1992, The American journal of pathology.

[19]  S. Greenberg.  Inclusion body myositis: Review of recent literature , 2009, Current neurology and neuroscience reports.

[20]  Steven A. Greenberg,et al.  Autoantibodies against a 43 KDa Muscle Protein in Inclusion Body Myositis , 2011, PloS one.

[21]  David Hilton-Jones,et al.  Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  Steven A Greenberg,et al.  Sarcoplasmic redistribution of nuclear TDP‐43 in inclusion body myositis , 2009, Muscle & nerve.

[23]  J. Kelly,et al.  Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins , 2009, Proceedings of the National Academy of Sciences.

[24]  A. Broccolini,et al.  TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis. , 2012, The American journal of pathology.

[25]  K J Felice,et al.  A pilot randomized trial of oxandrolone in inclusion body myositis , 2002, Neurology.

[26]  J. Ju,et al.  p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system , 2010, Autophagy.

[27]  A. Oldfors,et al.  Anti–T-lymphocyte globulin treatment in inclusion body myositis , 2003, Neurology.

[28]  R. Hohlfeld,et al.  Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies , 1991, Annals of neurology.

[29]  J. Piette,et al.  CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. , 2004, Blood.

[30]  L. Servais,et al.  Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials , 2014, Neuromuscular Disorders.

[31]  M. Dalakas.  Polymyositis, dermatomyositis and inclusion-body myositis. , 1991, The New England journal of medicine.

[32]  A. Pestronk,et al.  Polymyositis: An overdiagnosed entity , 2004, Neurology.

[33]  C. Loddenkemper,et al.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease , 2007, The Journal of experimental medicine.

[34]  I. Targoff,et al.  Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies: Analysis of 100 French Canadian Patients , 2005, Medicine.

[35]  I. Lundberg,et al.  Expanded T cell receptor Vβ-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. , 2010, Arthritis and rheumatism.

[36]  Pietro Fratta,et al.  Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. , 2005, The American journal of pathology.

[37]  M. Dalakas,et al.  Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives , 2013, Expert review of clinical immunology.

[38]  B. De Paepe,et al.  Role of cytokines and chemokines in idiopathic inflammatory myopathies , 2009, Current opinion in rheumatology.

[39]  Andrew G Engel,et al.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM , 2008, Neurology.

[40]  I. Ferrer,et al.  Expression of mutant ubiquitin (UBB+1) and p62 in myotilinopathies and desminopathies , 2007, Neuropathology and applied neurobiology.

[41]  Randomized pilot trial of high-dose βINF-1a in patients with inclusion body myositis , 2004, Neurology.

[42]  H. Ploegh,et al.  Autoantibodies Produced at the Site of Tissue Damage Provide Evidence of Humoral Autoimmunity in Inclusion Body Myositis , 2012, PloS one.

[43]  I. Nishino,et al.  Allelic heterogeneity of GNE gene mutation in two Tunisian families with autosomal recessive inclusion body myopathy , 2005, Neuromuscular Disorders.

[44]  M. Toepfer,et al.  High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study , 2000, Journal of Neurology.

[45]  A. Berrebi,et al.  Human monoclonal antibody derived from an autoimmune thrombocytopenic purpura patient, recognizing an intermediate filament's determinant common to vimentin and desmin. , 1990, Clinical immunology and immunopathology.

[46]  C. Duyckaerts,et al.  Th1 Response and Systemic Treg Deficiency in Inclusion Body Myositis , 2014, PloS one.

[47]  I. James,et al.  Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): A population control study , 2012, Journal of Neuroimmunology.

[48]  David Hilton-Jones,et al.  Long-term observational study of sporadic inclusion body myositis. , 2011, Brain : a journal of neurology.

[49]  Wolfgang Müller-Felber,et al.  A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation , 2003, Neuromuscular Disorders.

[50]  J. Mendell,et al.  Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. , 1991, Archives of neurology.

[51]  W. Engel,et al.  β-amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis , 1992, The Lancet.

[52]  R. Hohlfeld,et al.  Inclusion Body Myositis , 2006, Neurology.

[53]  M. Dalakas,et al.  Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle. , 2012, Arthritis and rheumatism.

[54]  Olivier Boyer,et al.  Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. , 2006, Brain : a journal of neurology.

[55]  N. Lévy,et al.  Translational Research and Therapeutic Perspectives in Dysferlinopathies , 2011, Molecular medicine.

[56]  M. Sandri,et al.  Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies , 2013, Journal of Cell Science.

[57]  G. Borm,et al.  Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. , 2004, Journal of neurology, neurosurgery, and psychiatry.

[58]  R. Gold,et al.  Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death. , 2012, Brain : a journal of neurology.

[59]  J. Verschuuren,et al.  A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. , 2011, Brain : a journal of neurology.

[60]  V. Askanas,et al.  p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis , 2009, Acta Neuropathologica.

[61]  A. Engel,et al.  Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. , 1989, Human pathology.

[62]  M. Dalakas,et al.  Inclusion body myositis and myopathies , 1997, Journal of the Neurological Sciences.

[63]  A. Engel,et al.  Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells , 1984, Annals of neurology.

[64]  I. Nonaka,et al.  Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice. , 2014, Brain : a journal of neurology.

[65]  M. Dalakas,et al.  Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. , 2009, The Journal of clinical investigation.

[66]  J. Verschuuren,et al.  Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis , 2004, Neurology.

[67]  M. Rose,et al.  International Workshop : Inclusion Body Myositis , 2 – 4 December 2011 , Naarden , The Netherlands , 2013 .

[68]  M. Dalakas,et al.  Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. , 2004, Brain : a journal of neurology.

[69]  R. Wada,et al.  Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[70]  A. Pestronk,et al.  TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[71]  G. Pinkus,et al.  Plasma cells in muscle in inclusion body myositis and polymyositis , 2005, Neurology.

[72]  I. Nonaka,et al.  Mutation profile of the GNE gene in Japanese patients with distal myopathy with rimmed vacuoles (GNE myopathy) , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[73]  J. Rauch,et al.  Hybridoma lupus autoantibodies can bind major cytoskeletal filaments in the absence of DNA-binding activity. , 1988, Arthritis and rheumatism.

[74]  M. Dalakas,et al.  HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies , 1998, Journal of Neuroimmunology.

[75]  Frank M LaFerla,et al.  Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. , 2006, The American journal of pathology.

[76]  Robert W. Taylor,et al.  Mitochondrial and inflammatory changes in sporadic inclusion body myositis , 2015, Neuropathology and applied neurobiology.

[77]  I. Nishino,et al.  Cell stress molecules in the skeletal muscle of GNE myopathy , 2013, BMC Neurology.

[78]  W. Engel,et al.  Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. , 2010, The American journal of pathology.

[79]  Olivier Boyer,et al.  Long‐term persistence of clonally expanded T cells in patients with polymyositis , 2004, Annals of neurology.

[80]  T. Maisonobe,et al.  Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis , 2011, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[81]  Hanno Steen,et al.  Cytosolic 5′‐nucleotidase 1A autoimmunity in sporadic inclusion body myositis , 2013, Annals of neurology.

[82]  I. Nonaka,et al.  Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model , 2009, Nature Medicine.

[83]  W. Engel,et al.  Sporadic inclusion-body myositis: A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. , 2015, Biochimica et biophysica acta.

[84]  H. Langen,et al.  Antibody‐based proteomics and biomarker research—Current status and limitations , 2014, Proteomics.

[85]  F. Heppner,et al.  Luminescent Conjugated Oligothiophenes for Sensitive Fluorescent Assignment of Protein Inclusion Bodies , 2013, Chembiochem : a European journal of chemical biology.

[86]  David Hilton-Jones,et al.  A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis , 2014, BMJ Open.

[87]  Marinos C. Dalakas,et al.  β‐Amyloid is a substrate of autophagy in sporadic inclusion body myositis , 2007 .

[88]  S. Kong,et al.  Fast‐twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis , 2009, Muscle & nerve.

[89]  Lippincott Williams Wilkins,et al.  Randomized pilot trial of βINF1a (Avonex) in patients with inclusion body myositis , 2002, Neurology.

[90]  F. LaFerla,et al.  Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase‐3β , 2008, Annals of neurology.

[91]  J. Winkles,et al.  TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. , 2003, Cytokine & growth factor reviews.

[92]  W. Engel,et al.  Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. , 2011, Presse medicale.

[93]  W. F. Abdo,et al.  Increased plasma amyloid-β42 protein in sporadic inclusion body myositis , 2009, Acta Neuropathologica.

[94]  A. Pestronk.  Acquired immune and inflammatory myopathies: pathologic classification , 2011, Current opinion in rheumatology.

[95]  D. Piwnica-Worms,et al.  Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease , 2009, The Journal of cell biology.

[96]  David Hilton-Jones,et al.  International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009 , 2010, Neuromuscular Disorders.

[97]  A. Filipovich,et al.  Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome , 2002, Journal of medical genetics.

[98]  S. Greenberg.  Comment on alemtuzumab and inclusion body myositis. , 2010, Brain : a journal of neurology.

[99]  M. Dalakas,et al.  Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. , 2000, Brain : a journal of neurology.

[100]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[101]  W. Engel,et al.  Dysferlin is a newly identified binding partner of AβPP and it co-aggregates with amyloid-β42 within sporadic inclusion-body myositis (s-IBM) muscle fibers , 2013, Acta Neuropathologica.

[102]  M. Weller,et al.  Human muscle cells express a B7‐related molecule, B7‐H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[103]  Allan D. Kirk,et al.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis , 2009, Brain : a journal of neurology.

[104]  Friedell Gh.  DRUGS IN HOSPITAL. , 1965 .

[105]  F. Authier,et al.  Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the unfolded protein response. , 2013, The American journal of pathology.

[106]  J. Dambrosia,et al.  Treatment of inclusion-body myositis with IVIg , 1997, Neurology.

[107]  A. Engel,et al.  Sporadic inclusion body myositis: Counts of different types of abnormal fibers , 1996, Annals of neurology.